Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease - Takeaways - MDSpire

Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease

  • By

  • Jennifer L Gill

  • Aurelio Miracolo

  • Konstantina Politopoulou

  • Efstratios A Apostolou

  • Sahan A Jayawardana

  • Alex W Carter

  • Panos G Kanavos

  • January 13, 2026

  • 0 min

Share

  • 1

    Cardiovascular disease accounts for nearly four million deaths annually in Europe, costing the EU €282 billion each year.

  • 2

    Optimizing secondary prevention of atherosclerotic cardiovascular disease (ASCVD) could yield over 94,000 cardiovascular-event-free life-years annually across seven European countries.

  • 3

    Improving treatment coverage for hypertension, hypercholesterolaemia, diabetes, and smoking cessation to 70% is essential for enhancing ASCVD outcomes.

  • 4

    There exists a significant gap between ASCVD prevention guidelines and their real-world implementation across Europe.

  • 5

    Future cardiovascular health plans should focus on proactive patient identification and timely treatment to reduce mortality and improve health outcomes.

Original Source(s)

Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease

  • by Jennifer L Gill, Aurelio Miracolo, Konstantina Politopoulou, Efstratios A Apostolou, Sahan A Jayawardana, Alex W Carter, Panos G Kanavos

  • January 13, 2026

Related Content

Serum uric acid levels and cardiorenal complication prevalence in hypertensive patients before and after the COVID-19 pandemic: a retrospective cross-sectional study from a tertiary traditional Chinese medicine hospital

Machine Learning Prediction Model for Dyslipidemia and Its Association With Atherothrombotic Events in 3 Independent Cohorts From South Korea, Japan, and the United Kingdom: Algorithm Development and Validation Study

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.